US4404131A - Method of producing a factor-VIII(AHF)-high-concentrate - Google Patents

Method of producing a factor-VIII(AHF)-high-concentrate Download PDF

Info

Publication number
US4404131A
US4404131A US06/287,912 US28791281A US4404131A US 4404131 A US4404131 A US 4404131A US 28791281 A US28791281 A US 28791281A US 4404131 A US4404131 A US 4404131A
Authority
US
United States
Prior art keywords
ahf
viii
factor
precipitate
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/287,912
Other languages
English (en)
Inventor
Otto Schwarz
Yendra Linnau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG fuer Chemisch Medizinische Produkte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG fuer Chemisch Medizinische Produkte
Assigned to IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE reassignment IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: LINNAU, YENDRA, SCHWARZ, OTTO
Application granted granted Critical
Publication of US4404131A publication Critical patent/US4404131A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions
US06/287,912 1980-08-27 1981-07-29 Method of producing a factor-VIII(AHF)-high-concentrate Expired - Fee Related US4404131A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0433880A AT369263B (de) 1980-08-27 1980-08-27 Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
AT4338/80 1980-08-27

Publications (1)

Publication Number Publication Date
US4404131A true US4404131A (en) 1983-09-13

Family

ID=3562706

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/287,912 Expired - Fee Related US4404131A (en) 1980-08-27 1981-07-29 Method of producing a factor-VIII(AHF)-high-concentrate

Country Status (19)

Country Link
US (1) US4404131A (fi)
JP (1) JPS5928537B2 (fi)
AR (1) AR228874A1 (fi)
AT (1) AT369263B (fi)
BE (1) BE890003A (fi)
CA (1) CA1160567A (fi)
CH (1) CH652030A5 (fi)
DE (1) DE3129987C2 (fi)
DK (1) DK156764C (fi)
ES (1) ES8302017A1 (fi)
FI (1) FI72653C (fi)
FR (1) FR2489150A1 (fi)
GB (1) GB2083047B (fi)
HU (1) HU183542B (fi)
IT (1) IT1138511B (fi)
LU (1) LU83577A1 (fi)
NL (1) NL8103563A (fi)
NO (1) NO157884C (fi)
SE (1) SE459639B (fi)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4739039A (en) * 1985-11-08 1988-04-19 Baxter Travenol Laboratories, Inc. Method for preparing antihemophilic factor (AHF) by cold precipitation and for improving solubility of recovered AHF product
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US5824780A (en) * 1993-07-23 1998-10-20 Baxter International Inc. Activated human factor VIII and method of preparation
US20030078384A1 (en) * 2001-10-19 2003-04-24 Joshua Levy Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU555305B2 (en) * 1982-09-29 1986-09-18 Bayer Corporation Antihemophilic factor concentrate
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3869436A (en) * 1971-06-01 1975-03-04 Statens Bakteriologiska Lab Method for fractionating plasma proteins using peg and ion-exchangers
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
AT349639B (de) 1976-08-14 1979-04-10 Recherches Hematologiques Verfahren zum aufkonzentrieren und reinigen des antihaemophiliefaktors
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
DE2624373C2 (de) 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1101332A (fr) * 1976-01-30 1981-05-19 Edward Shanbrom Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3869436A (en) * 1971-06-01 1975-03-04 Statens Bakteriologiska Lab Method for fractionating plasma proteins using peg and ion-exchangers
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
DE2624373C2 (de) 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
AT349639B (de) 1976-08-14 1979-04-10 Recherches Hematologiques Verfahren zum aufkonzentrieren und reinigen des antihaemophiliefaktors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Arkiv for Kemi, 12, pp. 387-396 (1958). *
Chem. Abst. 76:22762w. *
J. Amer. Chem. Soc. 68, 459 (1946). *
Johnson, A., Vox Sang 36(2) 1979, pp. 72-76-Abst. *
Proc. 11th Congr. Int. Soc. Blood Transf., No. 29, Part 4, p. 1109 (1966). *
Simonetti, et al., Hemostase 1, 57, (1961). *
The New England Journal of Medicine 273, pp. 1443-1446 (1965). *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
US5618789A (en) * 1984-04-20 1997-04-08 Genentech, Inc. Functional human factor VIII
US5683905A (en) * 1984-04-20 1997-11-04 Genentech, Inc. Vectors and cell lines capable of correctly splicing exon regions
US5668108A (en) * 1984-04-20 1997-09-16 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
US5654147A (en) * 1984-04-20 1997-08-05 Genentech, Inc. Method of hybridization using oligonucleotide probes
US5633150A (en) * 1984-04-20 1997-05-27 Genentech, Inc. Preparation of functional human factor VIII
US5618788A (en) * 1984-04-20 1997-04-08 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4739039A (en) * 1985-11-08 1988-04-19 Baxter Travenol Laboratories, Inc. Method for preparing antihemophilic factor (AHF) by cold precipitation and for improving solubility of recovered AHF product
US5824780A (en) * 1993-07-23 1998-10-20 Baxter International Inc. Activated human factor VIII and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US20060205661A1 (en) * 1999-02-22 2006-09-14 Baxter International, Inc. Novel albumin-free factor VIII formulations
US9352027B2 (en) 1999-02-22 2016-05-31 Baxalta Incorporated Albumin-free factor VIII formulations
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
US9669076B2 (en) 1999-02-22 2017-06-06 Baxalta Incorporated Albumin-free factor VIII formulations
US20040116345A1 (en) * 1999-02-22 2004-06-17 Marc Besman Novel albumin-free factor VIII formulations
US8765665B2 (en) 1999-02-22 2014-07-01 Baxter International Inc. Albumin-free factor VIII formulations
US8372800B2 (en) 1999-02-22 2013-02-12 Baxter International Inc. Albumin-free factor VIII formulations
US8058226B2 (en) 1999-02-22 2011-11-15 Baxter International Inc. Albumin-free factor VIII formulations
US7087723B2 (en) 1999-02-22 2006-08-08 Baxter International Inc. Albumin-free factor VIII formulations
US7247707B2 (en) 1999-02-22 2007-07-24 Baxter International Inc. Albumin-free factor VIII formulations
US7125552B2 (en) 2001-10-19 2006-10-24 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20030078384A1 (en) * 2001-10-19 2003-04-24 Joshua Levy Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20050209442A1 (en) * 2001-10-19 2005-09-22 Joshua Levy Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20050080238A1 (en) * 2001-10-19 2005-04-14 Joshua Levy Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2003034982A2 (en) * 2001-10-19 2003-05-01 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2003034982A3 (en) * 2001-10-19 2003-11-06 Hemacare Corp Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
US10512674B2 (en) 2008-11-07 2019-12-24 Baxalta Incorporated Factor VIII formulations
US11020459B2 (en) 2008-11-07 2021-06-01 Baxalta Incorporated Factor VIII formulations
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Also Published As

Publication number Publication date
NO157884B (no) 1988-02-29
IT8123660A0 (it) 1981-08-27
BE890003A (fr) 1981-12-16
DE3129987C2 (de) 1984-11-29
DE3129987A1 (de) 1982-04-22
ES504859A0 (es) 1983-01-01
JPS5775928A (en) 1982-05-12
FI812567L (fi) 1982-02-28
FR2489150B1 (fi) 1984-06-29
SE8104482L (sv) 1982-02-28
CH652030A5 (de) 1985-10-31
JPS5928537B2 (ja) 1984-07-13
ATA433880A (de) 1982-05-15
NL8103563A (nl) 1982-03-16
LU83577A1 (de) 1981-12-01
NO812905L (no) 1982-03-01
GB2083047A (en) 1982-03-17
SE459639B (sv) 1989-07-24
NO157884C (no) 1988-06-15
DK156764B (da) 1989-10-02
ES8302017A1 (es) 1983-01-01
DK156764C (da) 1990-02-19
DK360281A (da) 1982-02-28
FR2489150A1 (fr) 1982-03-05
CA1160567A (en) 1984-01-17
FI72653C (fi) 1987-07-10
AR228874A1 (es) 1983-04-29
FI72653B (fi) 1987-03-31
IT1138511B (it) 1986-09-17
HU183542B (en) 1984-05-28
GB2083047B (en) 1984-03-28
AT369263B (de) 1982-12-27

Similar Documents

Publication Publication Date Title
US4404131A (en) Method of producing a factor-VIII(AHF)-high-concentrate
US4203891A (en) Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US4670544A (en) Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it
US4754019A (en) Method of producing substantially pure albumin using carboxylic acids and ammonium sulfate
EP0148843B1 (en) A concentrate of the antihemophilic factor viii and a process for producing it
EP0127603B1 (de) Verfahren zur Herstellung einer Faktor VIII(AHF)-hältigen Präparation
AT391808B (de) Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
JPH0348888B2 (fi)
US4348315A (en) Process in purification and concentration of the factor VIII-complex
US4294826A (en) Process for the preparation of highly purified antihemophilic factor
HU204282B (en) Process for producing albumine-solutions purified with anionic detergent
US4977246A (en) High recovery process for antihemophilic factor
JPH0822879B2 (ja) 冷沈澱により抗血友病因子を製造し且つ得られる抗血友病因子製品の溶解度を改善するための方法
US4197238A (en) Method of preparation of human albumin using polyethylene glycol
JPS61189228A (ja) 血液凝固第８因子製剤の製法
ATE44750T1 (de) Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats.
JPS6242887B2 (fi)
SU1127525A3 (ru) Способ выделени альбумина
EP0076870B1 (en) Process for the preparation of highly purified antihemophilic factor
WO1988008004A1 (en) Extraction of factor viii
JPH0345080B2 (fi)
SU467536A1 (ru) Способ получени сывороточного альбумина
AGREN The Purification of Aminopolypeptidase from the Hog's pyloric Mucosa. III.
JPS5625114A (en) Preparation of human gamma globulin
JPH06311883A (ja) プラスミノゲンの製造方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SCHWARZ, OTTO;LINNAU, YENDRA;REEL/FRAME:003904/0981

Effective date: 19810617

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19950913

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362